DOCSLIB.ORG

Clozapine and Obsessive-Compulsive Symptoms Across Major Psycho=C Disorders - a Review of Three Cases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clozapine and Obsessive-Compulsive Symptoms Across Major Psycho=C Disorders - a Review of Three Cases Clozapine and Obsessive-Compulsive Symptoms Across Major Psycho=c Disorders - a Review of Three Cases. P.1.g.069 Salta M.1, Mendes S.1, Gamito A.1 1Setúbal Hospital Centre, Setúbal, Portugal Background Clozapine is the single most effecCve drug to treat refractory schizophrenia and other resistant psychiatric disorders presenCng with psychoCc symptoms. In schizophrenia it also demonstrates anC-suicidal effects. Its main acCons are strong serotoninergic antagonism on 5-HT2A, 5-HT1C and 5-HT2C receptors, and less powerful dopaminergic antagonism on D2 and D4 receptors. It also acts on adrenergic, muscarinic and histaminic receptors. These acCons account for its clinical indicaCons but also for its adverse effects. One of these is the emergence of de novo obsessive and compulsive symptoms (OCS), with a prevalence of 20-70% reported in the literature. These are related to the duraCon of treatment and dose prescribed. The cases are mainly reported in schizophrenic but also in schizoaffecCve and bipolar paCents. The mechanism for the OCS is not fully known, but neuroimaging and geneCc studies are being developed to unravel this. Methods and Results The following are the descripCons of the cases of three paCents, the first ones diagnosed with schizophrenia and the other diagnosed with schizoaffecCve disorder, with a long-term follow up in a private pracCce – 15 to 19 years, to whom clozapine was prescribed at a certain point during their treatment, and that developed de novo obsessive thoughts and compulsive behaviours.. SR, male, 38 years old, born in Mozambique, worked in PT, male, 36 years old, born in Lisbon, 8th grade ES, female, 40 years old, born in Lisbon, 9th grade trading, single, no offspring. Daily cannabis and sporadic complete, single, no offspring. No toxic habits or medical complete, in a relaConship, no offspring. Daily cannabis alcohol consumpCon. Asthma. No known mental illness condiCons. No known mental illness in the family. consumpCon. No medical condiCons. Sister diagnosed in the family. with bipolar disorder type IV. September 2001 June 1997 February 1997 First appointment at age 20. Three months earlier: anxiety, First appointment at age 18. Since age 15: school and social First appointment at age 26. Diagnosed with schizophrenia, takes adenCon and concentraCon deficits, anhedonia, thought funcConing deterioraCon. Two months before appointment: risperidone 6mg + lorazepam 3 mg. Has persecutory delusions broadcasCng with insight, feelings of self-reference iniCally with overvalued ideas of persecutory type, delusional ideas of self- and delusional percepCons. Akathisic. Starts clozapine =tra=on insight, then in a delusional form, 3rd person commenCng verbal reference, delusion of control and thought broadcasCng, un=l 300mg/day. Stops risperidone. Gets beder. CogniCve hallucinaCons, thought echo and insomnia. Was euthymic. R/ delusional mood. R/ risperidone 2mg + lorazepam 2,5mg. deficits. Wants to stop medicaCon because of hypersalivaCon. pimozide 2mg, lorazepam 2,5mg, cyamemazine 40-60mg and 2002-2003 biperiden retard 4 mg. PosiCve symptoms beder, then stable, negaCve symptoms Stable, beder self-care. No insight, stops medicaCon - > psychoCc slightly beder – tried to return to work. Akathisia and acute outbreak. Restarts clozapine with progressive stability. Compliant to treatment. Remission of psychoCc symptoms. Was dystonic reacCons with a small dose of risperidone. Starts 2004-2005 on haloperidol then risperidone prescribed by another doctor. thioridazine 25mg 3/day. Episode of acute oculomotor dystonia, Rumina=ons in the form of contamina=on fear: afraid of geSng Started studying at the University. Reports “feeling lazy”. Blunted managed with biperiden. AIDS s=nging herself with needles that can be everywhere like affect and apathy. 1998-1999 the street floor. Starts verifica=on and washing rituals. R/ 1998 Stable. AffecCvity slightly beder. Didn’t manage to get back to Sertraline 100mg – non-compliance. Later, depressive mood and Stopped going to University. Neglect of self-care. Oro-buco-facial previous work, starts playing in a music band. Switch to OCS. R/ lorazepam 2,5mg 2/day. dystonic movements. Poor thought content and abstracCon olanzapine -> negaCve symptom improvement. 2006 deficits. Loosening of associaCons. Was feeling bad on 2000 Agoraphobia with panic adacks, depressed. R/ paroxeCne 20mg, risperidone. Blood count ok. Starts clozapine =tra=on un=l Worsening of negaCve symptoms. Starts clozapine, =trated un=l took only 10mg. Reports listening to an “inner voice” saying her 300mg/day. Then, voliCon slightly beder, more acCve and with 300mg. AvoliCon beder. to “kill your father”. ↑ Clozapine to 400mg, ↑paroxeCne to 2001 beder performance at everyday tasks. Taking Clozapine 300mg/ 20mg. Then slightly beder. Takes clozapine 400mg, and day. Stops pimozide. CogniCve training of everyday acCviCes. Feels beder, more lorazepam 2,5mg 2/day, only 10mg of paroxeCne. Later, reports 1999 acCve, plans of recording a CD. overvalued paranoid ideas. Stops paroxeCne. Later, is afraid of DayCme spleepiness, some anxiety, incipient negaCve symptoms. 2002 being poisoned with milk. 2007 Clozapine dose adjustments. Feelings of “having two persons inside”, thoughts about his 2000 mother and brothers’ death. ↑ Clozapine to 400mg/daily. Starts Doesn’t leave the house nor drinks milk or juices. R/ lamotrigine kept complaints of dayCme sleepiness. Switch to olanzapine 10 to have obsessive rumina=ons and intrusive thoughts of sexual 100mg, non-compliance. Reduced clozapine to 300mg. mg then 20mg was tried – stopped clozapine for 2 months. contents. R/ fluvoxamine 100mg/daily. Then obsessive thoughts Overvalued ideas of poisoning, phobic symptoms and cleaning Worsening of the clinical picture with posiCve symptoms slightly beder. Secondary effects: tremor, blurred vision, urinary rituals. Hypersomnia, hyperphagia. resurgence. Restarts clozapine Ctrated to 300mg. urgency -> dose adjustments. Later, new agudizaCon of obsessive 2008-2010 2001 thoughts. Fluvoxamine -> sertraline 100mg. ↓ clozapine to Persecutory delusions: wants to change the door lock of her PsychoCc symptoms stable. Had one panic adack and complains 300mg/day. By the end of the year has control over obsessive house, atypical depressive and phobic symptoms. Refuses to run of globus histericus. Starts lorazepam 2,5mg. thoughts, less intrusive ideas. keeps clozapine 300mg + sertraline blood tests being afraid of having HIV. VerificaCon rituals. Only 2002 100mg. taking clozapine 300mg/day, always refused lamotrigine. By the 2003-2007 PsychoCc symptoms stable. Agoraphobia. Starts fluvoxamine end of 2010 has again anxiety and new panic adacks. R/ 100mg and cetazolam 30mg. Stops lorazepam. Reports Stable. Starts a computer course. citalopram 10mg + clonazepam 2mg. worsening of anxiety and mood lability. Fluvoxamine is stopped. 2008 2011 2003 Took by mistake 100mg of his mothers’ fluoxeCne at bed Cme -> No panic adacks. Non-compliance to citalopram. Taking clozapine SCll has anxiety symptoms of changing intensity. Benzodiazepine worsening of psychoCc symptoms, then was back to baseline. + clonazepam. Winter: again delusional convicCon that “they dose adjusted. Clozapine at 300mg. Stops sertraline, starts lamotrigine 100mg/day. ↓ clozapine to have her house-door keys”. Suicidal ideaCon but no intenCon. 2004 200mg. 2012-2013 2009 Develops obsessive symptoms: verifica=on rituals of the car and FluctuaCon of psychoCc symptoms. Takes lamotrigine 50mg/day. house doors -> symptoms didn’t interfere with funcConality, is Stable, more acCve, no obsessive symptoms. + clozapine 300mg + clonazepam 2mg. Then stops lamotrigine. working with his father at a store. 2010-2016 2014 2005- 2016 Except for some periods of self-reference ideas, kept clinically New depressive episode, now with hapCc hallucinaCons, and PsychoCc symptoms stable. SCll some obsessive symptoms with stable. again delusional percepCons. Worsening of the clinical picture modest impact on everyday life. Remission of anxiety symptoms. with citalopram. R/ amisulpride 200mg, with efficacy. Later again Stable with clozapine 300mg only. more depressed with worsening of persecutory ideas and obsessive rituals. keeps taking amisulpride 200mg + clozapine 300mg. 2015-2016 Beder. Reduced clozapine to 200mg/day. Sazonality, with remission of depressive symptoms and less intensity of the obsessive symptoms in the Spring. No insight for persecutory ideas. Regular medicaCon: clozapine 200mg + amisulpride 200mg + clonazepam 2mg. Conclusions It is worth noCcing that the paCents had no OCS at presentaCon nor in their premorbid history nor traits or full blown obsessive personality disorder. All developed OCS aWer the introducCon of clozapine to their treatment, seven and two years for the 2 paCents with schizophrenia, and three years for the paCent with schizoaffecCve disorder. The strategies used for each case are according to the ones used in several studies and case reports. Pharmacological therapeuCc opCons include clozapine dose reducCon and/or adding another drug to the treatment, namely, specific serotonin receptor antagonists like sertraline, fluvoxamine or fluoxeCne; a tricyclic anCdepressant like clomipramine; a dopamine and serotonin receptor parCal agonist like aripiprazole – proven to have anC-obsessive potency; a dopamine D2 and D3 receptor antagonist (like amisulpride) or a voltage-gated sodium channel blocker like lamotrigine. The fact that these drugs reduce secondary OCS support the theories about the mechanisms involved in their origin.
Load more

Recommended publications
  • Information for the Patient Losartan Potassium/Hydrochlorothiazide 100
    Package leaflet: Information for the patient Losartan Potassium/Hydrochlorothiazide 100 mg/12.5 mg Film-coated Tablets (losartan potassium/hydrochlorothiazide) Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Losartan Potassium/Hydrochlorothiazide is and what it is used for 2. What you need to know before you take Losartan Potassium/Hydrochlorothiazide 3. How to take Losartan Potassium/Hydrochlorothiazide 4. Possible side effects 5. How to store Losartan Potassium/Hydrochlorothiazide 6. Contents of the pack and other information 1. What Losartan Potassium/Hydrochlorothiazide is and what it is used for Losartan Potassium/Hydrochlorothiazide is a combination of an angiotensin II receptor antagonist (losartan) and a diuretic (hydrochlorothiazide). Angiotensin II is a substance produced in the body which binds to receptors in blood vessels, causing them to tighten. This results in an increase in blood pressure. Losartan prevents the binding of angiotensin II to these receptors, causing the blood vessels to relax which in turn lowers the blood pressure. Hydrochlorothiazide works by making the kidneys pass more water and salt.
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Antipsychotics
    The Fut ure of Antipsychotic Therapy (page 7 in syllabus) Stepp,,hen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry Universityyg of California, San Diego School of Medicine Honorary Visiting Senior Fellow, Cambridge University, UK Sppyonsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. Copyright © 2011 Neuroscience Education Institute. All rights reserved. Individual Disclosure Statement Faculty Editor / Presenter Stephen M. Stahl, MD, PhD, is an adjunct professor in the department of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge in the UK. Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Dey, Forest, Genomind, Lilly, Merck, Pamlab, Pfizer, PGxHealth/Trovis, Schering-Plough, Sepracor/Sunovion, Servier, Shire, Torrent Consultant/Advisor: Advent, Alkermes, Arena, AstraZeneca, AVANIR, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Cypress, Dainippon Sumitomo, Dey, Forest, Genomind, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Merck, Neuronetics, Novartis, Ono, Orexigen, Otsuka, Pamlab, Pfizer, PGxHealth/Trovis, Rexahn, Roche, Royalty, Schering-Plough, Servier, Shire, Solvay/Abbott, Sunovion/Sepracor, Valeant, VIVUS, Speakers Bureau: Dainippon Sumitomo, Forest, Lilly, Merck, Pamlab, Pfizer, Sepracor/Sunovion, Servier, Wyeth Copyright © 2011 Neuroscience Education Institute. All rights reserved. Learninggj Objectives • Differentiate antipsychotic drugs from each other on the basis of their pharmacological mechanisms and their associated therapeutic and side effects • Integrate novel treatment approaches into clinical practice according to best practices guidelines • Identify novel therapeutic options currently being researched for the treatment of schizophrenia Copyright © 2011 Neuroscience Education Institute.
    [Show full text]
  • Drugs with Anticholinergic Properties, Cognitive Decline, and Dementia in an Elderly General Population: the 3-City Study
    Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Isabelle Carrière, Annie Fourrier-Reglat, Jean-François Dartigues, Olivier Rouaud, Florence Pasquier, Karen Ritchie, Marie-Laure Ancelin To cite this version: Isabelle Carrière, Annie Fourrier-Reglat, Jean-François Dartigues, Olivier Rouaud, Florence Pasquier, et al.. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly gen- eral population: the 3-city study.: Anticholinergics and cognitive dysfunction. Archives of Internal Medicine -New Series-, American Medical Association, 2009, 169 (14), pp.1317-24. 10.1001/archin- ternmed.2009.229. inserm-00415864 HAL Id: inserm-00415864 https://www.hal.inserm.fr/inserm-00415864 Submitted on 27 Jul 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Archives of Internal Medicine in press Abstract: 248 words Text: 3441 words Number of Tables: 4 Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population. The Three-City
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • Emea/666243/2009
    European Medicines Agency London, 29 October 2009 EMEA/666243/2009 ISSUE NUMBER: 0910 MONTHLY REPORT PHARMACOVIGILANCE WORKING PARTY (PHVWP) OCTOBER 2009 PLENARY MEETING The CHMP Pharmacovigilance Working Party (PhVWP) held its October 2009 plenary meeting on 19-21 October 2009. PhVWP DISCUSSIONS ON SAFETY CONCERNS Below is a summary of the discussions regarding non-centrally authorised medicinal products in accordance with the PhVWP publication policy (see under http://www.emea.europa.eu/htms/human/phv/reports.htm). Positions agreed by the PhVWP for non- centrally authorised products are recommendations to Member States. For safety updates concerning centrally authorised products and products subject to ongoing CHMP procedures, readers are referred to the CHMP Monthly Report (see under http://www.emea.europa.eu/pressoffice/presshome.htm). The PhVWP provides advice on these products to the Committee of Medicinal Products for Human Use (CHMP) upon its request. Antipsychotics - risk of venous thromboembolism (VTE) Identify risk factors for VTE for preventive action before and during treatment with antipsychotics The PhVWP completed their review on the risk of VTE of antipsychotics1. The review was triggered by and based on data from the UK spontaneous adverse drug reactions reporting system and the published literature. The PhVWP carefully considered the data, including the limitations of both information sources, such as the lack of randomised controlled trial data, the heterogeneity of published studies and the potential confounding factors such as sedation and weight gain, commonly present in antipsychotic users. The PhVWP concluded that an association between VTE and antipsychotics cannot be excluded. Distinguishing different risk levels between the various active substances was not possible.
    [Show full text]
  • Clozapine/Cyamemazine 985 Verse Effects, Clozapine Therapy Should Be Introduced Account
    Clozapine/Cyamemazine 985 verse effects, clozapine therapy should be introduced account. There have been a few reports of exacerbation of psy- Clozapine has shown consistent clinical benefit in schizophrenic chotic symptoms in patients who were switched to a generic for- patients with persistent aggressive or violent behaviour.2,9 gradually, beginning with low doses and increasing ac- 6,7 cording to response. mulation. Whether this is due to a sedative effect, a specific antiaggressive 1. Sajbel TA, et al. Converting patients from brand-name clozapine action, or just reflects an overall improvement in psychosis is un- In the treatment of schizophrenia, including reducing to generic clozapine. Ann Pharmacother 2001; 35: 281–4. known. 2. Makela EH, et al. Branded versus generic clozapine for treat- the risk of suicidal behaviour, the usual oral dose is ment of schizophrenia. Ann Pharmacother 2003; 37: 350–3. Clozapine has been advocated for use in schizophrenic patients 12.5 mg once or twice on the first day followed by 3. Stoner SC, et al. A program to convert patients from trade-name with moderate to severe tardive dyskinesia. It is still unclear 25 mg once or twice on the second day. Thereafter the to generic clozapine. Pharmacotherapy 2003; 23: 806–10. whether clozapine can itself cause tardive dyskinesia but some 4. Bazire S, Burton V. Generic clozapine in schizophrenia: what is patients with established tardive dyskinesia have experienced daily dosage may be increased gradually in steps of 25 all the fuss about? Pharm J 2004; 273: 720–1. improvement in their symptoms when using clozapine.10,11 to 50 mg to achieve a daily dose of up to 300 mg within 5.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,720,318 B2 Dib Et Al
    USOO6720318B2 (12) United States Patent (10) Patent No.: US 6,720,318 B2 Dib et al. (45) Date of Patent: Apr. 13, 2004 (54) COMBINATION OF CYAMEMAZINE AND EP O5295OO 3/1993 AN ATYPCAL NEUROLEPTIC EP O586.191 9/1994 EP O733634 9/1996 (75) Inventors: Michel Dib, Paris (FR); Cyrille wo WO 52. AC Leperlier, Fontainebleau (FR) WO 96/30375 10/1996 (73) Assignee: Aventis Pharma S.A., Antony Cedex WO WO 98/43646is 10/1998go (FR) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 Vanel et al., Eur. J. Clin. Pharmacol. (55, No. 9, 659–65, 1999) (abstract).* U.S.C. 154(b) by 0 days. Dietch, James T. et al., Aggressive Dyscontrol in Patients Treated with Benzodiazepines, J. Clin Psychiatry (1988, pp. (21) Appl. No.: 10/164,771 184-188, vol. 49:5). (22) Filed: Jun. 7, 2002 Overall, John E. et al., The Brief Psychiatric Rating Scale, Psychological Reports, (1962, pp. 799-812, vol. 10). (65) Prior Publication Data Senninger, J. L. et al., La Risperidone Dans Le Traitement de L'Agressivite Des Schizophrenes, Ann. Med. Psychol. US 2002/0183312 A1 Dec. 5, 2002 (1998, pp. 210-213, vol. 156 No. 3). Related U.S. Application Data Stimmel, Glen L., Benzodiazepines in Schizophrenia, Supplement to Pharmacotherapy (1996, pp. 148-151, vol. (63) Continuation of application No. PCT/FR00/03446, filed on 16). Dec. 8, 2000. Warneke, Lorne B., Benzodiazepines: Abuse and New Use, (30) Foreign Application Priority Data Can. J. Psychiatry (1991, pp. 194–205, vol.
    [Show full text]
  • The Anticholinergic Impregnation Scale: Towards The
    Therapie (2017) 72, 427—437 Available online at ScienceDirect www.sciencedirect.com CLINICAL PHARMACOLOGY The anticholinergic impregnation scale: Towards the elaboration of a scale adapted to prescriptions in French psychiatric settings L’échelle d’imprégnation anticholinergique : vers l’élaboration d’une échelle adaptée aux prescriptions en milieu psychiatrique franc¸ais a,b b,c,∗ Jeanne Briet , Hervé Javelot , c d Edwige Heitzmann , Luisa Weiner , c e Catherine Lameira , Philippe D’Athis , e a,b Marie Corneloup , Jean-Louis Vailleau a Pharmacy service, CHS de La Chartreuse, 21000 Dijon, France b PIC network (Psychiatrie Information Communication), EPSM Lille-Métropole, 59487 Armentières, France c Établissement public de santé Alsace Nord, 67170 Brumath, France d Psychiatry II and Inserm unit 1114, university hospital of Strasbourg, 67000 Strasbourg, France e Service of biostatistics and medical informatics, CHU de Dijon, 21000 Dijon, France Received 6 June 2016; accepted 23 December 2016 Available online 17 February 2017 KEYWORDS Summary Anticholinergics; Purpose. — Some drugs have anticholinergic activity and can cause peripheral or central side Anticholinergic drug effects. Several scales exist to evaluate the potential anticholinergic effect of prescribed drugs scale; but: (i) they are validated in the elderly and mainly assess the cognitive side effect of treat- Psychiatry ments; (ii) they do not concern some of the drugs frequently used in clinical psychiatry in France. The aim of our study is to develop a new scale, the anticholinergic impregnation scale (AIS), with drugs used in France and based on an assessment of the drugs used against peripheral anticholinergic adverse effects. ∗ Corresponding author. Clinical pharmacy service, Établissement public de santé Alsace Nord (EPS Alsace Nord), 141 avenue de Strasbourg, 67170 Brumath, France.
    [Show full text]
  • Drug Interactions with Proton Pump Inhibitor Or Infectious Etiologies? Sophie Wagner, M
    Confounding factors for variation of clozapine plasma levels: drug interactions with proton pump inhibitor or infectious etiologies? Sophie Wagner, M. G. Varet-Legros, Claudine Fabre, Jean Louis Montastruc, Haleh Bagheri To cite this version: Sophie Wagner, M. G. Varet-Legros, Claudine Fabre, Jean Louis Montastruc, Haleh Bagheri. Con- founding factors for variation of clozapine plasma levels: drug interactions with proton pump inhibitor or infectious etiologies?. European Journal of Clinical Pharmacology, Springer Verlag, 2010, 67 (5), pp.533-534. 10.1007/s00228-010-0925-z. hal-00638575 HAL Id: hal-00638575 https://hal.archives-ouvertes.fr/hal-00638575 Submitted on 6 Nov 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Page 3 of 8 European Journal of Clinical Pharmacology 1 2 Confounding factors for variation of clozapine plasma levels: drug interactions with 3 proton pump inhibitor or infectious aetiologies? 4 S Wagner 1, MG Varet-Legros 2, C Fabre 3, JL Montastruc 1, H Bagheri 1. 5 6 1 Service de Pharmacologie Clinique, Centre midi-pyrénées
    [Show full text]
  • PROPULSID® (Cisapride) Limited Access Program
    PROPULSID (cisapride) Limited Access Program Disallowed Medications and Foods List by Generic Name NOTE: THIS IS A LIST OF DRUGS AND FOODS THAT HAVE THE POTENTIAL FOR INTERACTION WITH CISAPRIDE. Formal studies have not proven the interaction of all of these drugs and foods. THIS LIST IS NOT COMPREHENSIVE AND IS SUBJECT TO REVISION AS ADDITIONAL INFORMATION BECOMES AVAILABLE. GENERIC NAME BRAND NAME CATEGORY Medications abiraterone ZYTIGA® A,C aclarubicin (only on Non Aclacin, Aclacinomycine, Aclacinon, Aclaplastin, A US Market) Jaclacin alfuzosin UROXATRAL® A amantadine Symmetrel®, Symadine® A amiodarone CORDARONE®, PACERONE®, GENERICS A,B,D amisulpride, sultopride Solian®, Barnotil, Topral, Barnetil, Barhemsys™ A amitriptyline, alone or in Elavil®, Tryptomer®, Tryptizol®, Laroxyl®, A,D any combination product Saroten®, Sarotex® Lentizol®, Endep®, GENERICS amphotericin B Fungilin®, Fungizone®, Abelcet®, AmBisome®, A,C Fungisome®, Amphocil®, Amphotec® amprenavir AGENERASE® A,B,D,E amsacrine (acridinyl Amsidine® A,B anisidide) anagrelide AGRYLIN®, XAGRID® A apalutamide ERLEADA™ A apomorphine Apokyn®, Ixense®, Spontane®, Uprima® A aprepitant Emend® B aripiprazole Abilify®, Aripiprex® A aripiprazole lauroxil Aristada™ A arsenic trioxide TRISENOX® A artemether and Coartem® A lumefantrine artenimol/piperaquine Eurartesim™ A,B,E asenapine Saphris®, Sycrest® A astemizole HISMANAL® A,E atazanavir REYATAZ® A,B atomoxetine Strattera® A azithromycin ZITHROMAX® A bedaquiline SIRTURO(TM) A bendroflumethiazide Aprinox, Naturetin® C benperidol ANQUIL®,
    [Show full text]
  • Binding of Levomepromazine and Cyamemazine to Human Recombinant Dopamine Receptor Subtypes
    Eur. J. Psychiat. Vol. 23, N.° 3, (147-152) 2009 Keywords: Clozapine; Cyamemazine; Dopamine receptor subtypes; Levomepromazine; Schizophre- nia. Binding of levomepromazine and cyamemazine to human recombinant dopamine receptor subtypes Lalit K. Srivastava*,** Neelakanta P.V. Nair*,** Samarthji Lal*,**,*** * Douglas Mental Health University Institute, Montreal, Quebec ** Department of Psychiatry, McGill University *** Department of Psychiatry, Montreal General Hospital, Montreal, Quebec CANADA ABSTRACT – Background and Objectives: Clozapine (CLOZ) and levomepromazine (LMP) improve treatment-resistant schizophrenia. The superior efficacy of CLOZ com- pared with other antipsychotic agents has been attributed to an effect on D1-like and D4 receptors. We examined the binding of LMP, CLOZ and cyamemazine (CMZ), a neu- roleptic analog of LMP, to human recombinant dopamine (rDA) receptor subtypes. Methods: Binding studies were performed on frozen membrane suspensions of human rDA receptor subtypes expressed in Sf9 cells. Results: (i) LMP has a high affinity (Ki, nM) for rD2 receptor subtypes (rD2L 8.6; rD2S 4.3; rD3 8.3; rD4.2 7.9); (ii) LMP and CLOZ have comparable affinities for the rD1 receptor (54.3 vs 34.6); (iii) CMZ has high affinities for rD2-like and rD1-like receptors (rD2L 4.6; rD2S 3.3; rD3 6.2; rD4.2 8.5; rD1 3.9; rD5 10.7); (iv) CMZ is 9 times more po- tent than CLOZ at the rD1 receptor and 5 times more potent than CLOZ at the rD4.2 re- ceptor; (v) CMZ has high affinities for rD1 and rD5 receptor subtypes compared with LMP and CLOZ. Conclusions: If D1 and D4 receptors are important sites for the unique action of CLOZ, the present study points to a need for clinical trials comparing CMZ with CLOZ in schizophrenia and in particular, treatment-resistant schizophrenia, especially given the risk for agranulocytosis with CLOZ.
    [Show full text]